Along with a crew of technologists and scientists, Jorge Soto is developing a simple, noninvasive, open-source test that looks for early signs of multiple forms of cancer. Onstage at TEDGlobal 2014, he demonstrates a working prototype of the mobile platform for the first time. TEDTalks is a daily video podcast of the best talks and performances from the TED Conference, where the world's leading thinkers and doers give the talk of their lives in 18 minutes (or less). Look for talks on Technology, Entertainment and Design -- plus science, business, global issues, the arts and much more. Find closed captions and translated subtitles in many languages at http://www.ted.com/translate Follow TED news on Twitter: http://www.twitter.com/tednews Like TED on Facebook: https://www.facebook.com/TED Subscribe to our channel: http://www.youtube.com/user/TEDtalksDirector
Views: 117513 TED
Panel of plasma microRNAs can be measured accurately to detect pancreatic cancer. Subscribe this channel to watch more motivational, inspirational, valuable and informative videos to soothe, cleanse and inspire your health, mind, body and spirit. Stay tuned and keep watching. Disclaimer:-- Any medical information published on this video is NOT intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. Copyright notice:-- "Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for "fair use" for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use."
Views: 109 Health • Mind • Body • Spirit
This talk was given at a local TEDx event, produced independently of the TED Conferences. Can we use micro-RNA to engineer a cure for skin cancer? In this inspiring talk, Larry Zhang shows how he created a new method to inhibit cancer cell growth in squamous cell carcinoma, and shares why "we will never find a cure for cancer." Larry Zhang, a recent high school graduate, has interned for the last three years at a biological research lab at the University of Colorado Boulder, where he is investigating skin cancer development. He is a three-time finalist at the Intel International Science and Engineering Fair for his work on RNA interference and skin cancer regulation. In the fall, he will be studying molecular biology and computer science at MIT in Cambridge, Mass. About TEDx, x = independently organized event In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x = independently organized TED event. The TED Conference provides general guidance for the TEDx program, but individual TEDx events are self-organized.* (*Subject to certain rules and regulations)
Views: 15221 TEDx Talks
TRACO 2014 - MicroRNA and inflammation; Genomics Air date: Monday, November 24, 2014, 4:00:00 PM Category: TRACO Runtime: 02:02:15 Description: TRACO Recent advances in understanding cancer biology are beginning to be translated into improvements in diagnosis and treatment of cancer. In the post-genome era, we increasingly rely on strong collaboration between basic and clinical scientists to develop novel approaches for treatment of human disease. The NCI Center for Cancer Research (CCR) is one of the largest cancer research organizations in the world, with more than 200 principal investigators, and has played a major role in development and implementation of many new technologies, such as nanotechnology, next generation sequencing, genomics and proteomics. For more information go to https://ccr.cancer.gov/trainee-resources-courses-workshops-traco Author: C. Harris, NIH; J. Wei, NIH Permanent link: http://videocast.nih.gov/launch.asp?18750
Views: 684 nihvcast
Download the app note from this talk here: http://bit.ly/15g6Qnf Dr. Malte Buchholz from the Clinic for Gastroenterology at the University of Marburg, Germany, discusses his pancreatic cancer research in this video. Learn how he measured and analyzed both microRNA and gene expression in the same sample, using a single Custom TaqMan Array Card
Views: 846 Thermo Fisher Scientific
©2012 German Science Day Dr. Klaus Giese, Chief Scientific Officer of Silence Therapeutics, presents at the German Science Day on 'The Pre-Clinical and Clinical Development of Atu027, a Liposomal siRNA, for Therapy in Oncology'. Slides for this talk can be found on SlideShare: http://slidesha.re/Atu027_ST Atu027, a novel RNAi therapeutic composed of liposomally formulated siRNA, is currently being tested in a Phase I clinical trial in oncology by Silence Therapeutics. This investigational drug targets the expression of PKN3 in the vascular endothelium and shows inhibition of tumor growth and strong anti-metastatic activity in various pre-clinical models. Latest developments on Atu027 are discussed in the video. For more information, please visit http://www.silence-therapeutics.com Or follow Silence Therapeutics on Twitter @RNAiHub: http://twitter.com/RNAiHub
Views: 3633 Silence Therapeutics
Understanding how a tumor switches from sustaining growth in just one part of the body to disseminating secondary tumors throughout the body, a process called metastasis, is a key goal of cancer research. Dr. Robert Weinberg and his colleagues have identified a microRNA that suppresses metastasis at several different stages of the process by virtue of its ability to coordinately target and repress a set of metastasis-promoting genes.
Views: 5953 Cell Press
Source - http://serious-science.org/videos/1516 Harvard Prof. Anna Krichevsky on role of microRNAs in cell differentiation, oncomiRs, and clinical trials
Views: 1208 Serious Science
This video will teach you about the deadly inflammation cycle and how it creates cancer so you can learn to prevent cancer or include strategies in you cancer care plan. For the PDF and other free videos sign up at http://CancerDecoded.net/
Views: 4827 Brigitta Schwulst
Charles L. Sawyers, MD delivers a lecture on overcoming drug resistance to Cancer therapies, one of a series of lectures from The Yale School of Medicine Bicentennial Symposium, "Biomedicine in the New Century," which took place over April 28--29, 2011.
Views: 6034 YaleUniversity
Media Project on the effect of PHD1 on Cep192 levels and the regulation of cell cycle progression. This video is based on a Developmental Cell publication by Sonia Rocha, a Principle Investigator in the Centre for Gene Regulation & Expression at the University of Dundee. References Original Research Paper Moser S.C., et al. PHD1 Links Cell-Cycle Progression to Oxygen Sensing through Hydroxylation of the Centrosomal Protein Cep192. Developmental Cell. 2013 Aug 8; 26(4): 381-392. Diagrams Stearns T. The Stearns Lab [Internet]. Stanford University Department of Biology and Genetics [cited 2013 Nov 20]. Available from: http://stearnslab.stanford.edu/WWD.html Ebert S. Mitosis. AP Biology. 2012 Aug 14 [cited 2013 Nov 20]. Available from: http://tinyurl.com/mzfl996 Smith B. Animal Cell Colouring. Smith Life Science [cited 2013 Nov 20]. Available from: http://www.smithlifescience.com/animalcellcolordefine.htm Software Sparkol® Videoscribe Pro. http://www.sparkol.com
Views: 4429 Daniel Bode
Get a better understanding of how inflammation promotes cancer. http://www.healthsynergy.ca This FREE 13 video series will give you a comprehensive understanding of what you can do to prevent and reverse cancer. For decades it's been know that inflammation promotes cancer, thus to prevent cancer, reduce inflammation. There are many sources of hidden inflammation so you need to track them all down and address them accordingly. This video will help you with that. Powerful empowering information you need to know. http://youtu.be/FpnwgRT_DRY
Views: 2633 Robert Ridpath
http://www.expressoshow.com/ In the world of medicine, scientists are making great strides in the fight against cancer. Using human cells grown in a lab, researchers from the US have figured out a way to stop cancer from growing or spreading. By regulating specific cells within the body called, microRNA’s. Stalk Expresso, we like it! Instagram: @expressoshow Facebook: Expresso Morning Show Twitter: @expressoshow Periscope: @expressoshow
Views: 28 Expresso Show
Dr Michael Clarke - Stanford School of Medicine, USA, speaking at AACR 2009: MicroRNAs regulating self renewal and breast cancer stem cells. Also preventing cancer cells from protecting themselves against radiation.
Views: 1209 ecancer
Turmeric Strikes at 'Main driver' of Cancerous Tumor Development, Study Finds. Turmeric is known for an extensive variety of advantages, a standout amongst the most encouraging being it's potential uses in the counteractive action and treatment of growth. Another investigation distributed in the diary Cancer Letters has investigated the dynamic hostile to malignancy part in turmeric—curcumin—and found that it can strike at the 'main driver' of dangerous tumor arrangement. The regular school of thought has constantly expected disease cells self-recharge, that the cells inside a tumor are kind of equivalents. Another school of thought, and one that is increasing more footing, is the one that takes a gander at cells known as malignancy undifferentiated organisms (CSC) and suggests that these kind of "mother" cells are at the highest point of disease cell chain of command and drive the development of tumors. Utilizing the ordinary model of malignancy and treating tumors with surgery, chemo, and radiation, we might have the capacity to "debulk" a tumor, however the foundational microorganisms may stay behind. At the point when this happens, does the tumor in the end return, as well as it does as such with a retaliation, being treatment-safe and frequently coming about as death. Rather, the CSC model of malignancy advancement and treatment concentrates exclusively on killing these mother cells, and in this way annihilating a tumors capacity to regrow. In the examination "Focusing on tumor undifferentiated organisms by curcumin and clinical applications", specialists took a gander at the different ways curcumin could affect malignancy foundational microorganisms and help to adequately treat different disease. They found that curcumin can specifically slaughter malignancy cells while keeping up solid cells. Now and again, it is really ready to work nearby customary chemotherapy, giving the traditional treatment more viability and reducing the unsafe symptoms. Further, curcumin has been found to adjust the statement of microRNAs, which manage an expected 33% of the protein-coding qualities in people, successfully attempting to smother tumor arrangement. At long last, as per Green Med Info, "curcumin appears to straightforwardly and in a roundabout way impact no less than three self-reestablishment pathways inside disease immature microorganisms, to be specific, Wnt/b-catenin, sonic hedgehog 89 (SHH), and Notch." "Curcumin, and also its modi?ed shapes (analogs or nanoparticle-epitomized definitions), has demonstrated awesome potential to hinder CSCs in a few sorts of tumor both in cell societies and in mouse models, including glioma, bosom, colorectal, pancreatic, mind, and esophageal diseases. A few analogs (e.g., CDF) and details (e.g., nanotechnology-based definition) have shown enhanced ef?cacy against CSC-like cells and more noteworthy development inhibitory limit in tumors. It is promising to assess curcumin and its modi?ed frames in different sorts of CSCs." All Photos Licensed Under CC Source : www.pexels.com www.pixabay.com www.commons.wikimedia.org
Views: 1787 Happy Life Tips
Memorial Sloan Kettering Cancer Center CEO Dr. Craig Thompson tells WSJ’s Simon Constable why he’s optimistic about new therapies aimed at increasing the body’s own ability to fight cancer. Photo: Andrew P. Leonard/Hanna Irie Subscribe to the WSJ channel here: http://bit.ly/14Q81Xy Visit the WSJ channel for more video: https://www.youtube.com/wsjdigitalnetwork More from the Wall Street Journal: Visit WSJ.com: http://online.wsj.com/home-page Follow WSJ on Facebook: http://www.facebook.com/wsjlive Follow WSJ on Google+: https://plus.google.com/+wsj/posts Follow WSJ on Twitter: https://twitter.com/WSJLive Follow WSJ on Instagram: http://instagram.com/wsj Follow WSJ on Pinterest: http://www.pinterest.com/wsj/ Follow WSJ on Tumblr: http://www.tumblr.com/tagged/wall-street-journal
Views: 9211 Wall Street Journal
For additional information visit http://www.cancerquest.org/frank-slack-interview. Dr. Frank Slack is Professor of Molecular, Cellular & Developmental Biology at Yale University. Dr. Slack's research is directed at understanding the role of microRNAs in cancer, both as possible treatments and as potential targets of therapy. MicroRNAs are small RNA molecules that are normally found in cells. They are able to control the activity of genes and alter the translation of messenger RNAs (mRNAs). The microRNAs present in a normal cell are not exactly the same as those in a cancer cell and that difference could be critical for many cancer types. In this interview, Dr Slack discusses the background to his interest in cancer biology. To learn more about cancer and watch additional interviews, please visit the CancerQuest website at http://www.cancerquest.org.
Views: 246 CancerQuest
Chronic inflammation and the chemical silencing of tumor-suppressing genes each play roles in development and progression of colorectal cancer. Research published in Nature Medicine led by MD Anderson Provost Raymond DuBois, M.D., Ph.D., connects the two factors by showing the inflammatory small molecule PGE2 silences genes via DNA methylation. http://www.nature.com/nm/journal/vaop/ncurrent/abs/nm.2608.html
Views: 2196 MD Anderson Cancer Center
https://www.ibiology.org/ibioseminars/microrna-biogenesis-regulation.html Part 1: microRNA Biogenesis and Regulation: Narry Kim takes us through the steps in microRNA biogenesis and explains the importance of microRNAs in regulating protein-coding mRNAs. Part 2: Tailing in the Regulation of microRNA and Beyond: Modifications, such as uridylation, of the 3’ tail of both microRNAs and mRNAs can regulate RNA function by targeting it for degradation. Talk Overview: Small RNAs (~20-30 nucleotides in length) are found in many eukaryotes and act to guard against unwanted RNA such as viruses, transposons and mRNAs. One family of small RNAs called microRNAs regulates protein-coding mRNAs by binding to the 3’UTR and repressing translation or inducing mRNA decay. microRNAs play a key role in animal development and diseases such as cancer. In her first talk, Dr. Narry Kim gives a step-by-step description of the microRNA biogenesis pathway and the points at which the pathway can be regulated. In her second talk, Kim focuses on the regulation of microRNA function. A small percentage of microRNAs are modified with untemplated nucleotides, usually A or U, added to their 3’ end or “tail”. “Tailing” can modify the microRNA function and in some cases it can act as a molecular switch resulting in developmental and pathological transitions. Kim’s lab was interested in knowing if tailing occurs on other RNAs such as mRNA. They developed a novel method to sequence the 3’ tail region of mRNA allowing them to measure polyA tail length and detect 3’ terminal modifications. Interestingly, they found widespread uridylation of mRNAs and showed that 3’ polyU modification serves to mark mRNA for decay. Speaker Biography: Narry Kim is Director of the Institute for Basic Science and a Professor at Seoul National University. Her lab studies RNA-mediated gene regulation using stem cells, early embryos, and neuronal cells as model systems. Kim received her BA and MS degrees in microbiology from Seoul National University and her DPhil in biochemistry from Oxford University. She was a postdoctoral fellow at the University of Pennsylvania in Gideon Dreyfuss’ lab before returning to Seoul National University as a faculty member. Kim is on the editorial board of a number of journals and has helped to organize many meetings on RNA biology. Her research and contributions to the life sciences community have been recognized with numerous awards including the Women in Science Award from L’Oreal-UNESCO (2008) and the Ho-Am Prize in medicine (2009). In 2014, Kim was elected to the Korean Academy of Science and Technology and the National Academy of Sciences USA. Learn more about Dr. Kim’s research here: http://www.narrykim.org/en/
Views: 6630 iBiology
A cancer research team led by Dean Tang, PhD, found a specific miRNA (or microRNA) molecule that stunts prostate cancer spread. Dr. Tang, Roswell Park's Chair of Pharmacology and Therapeutics, explains how miR-141 may play a role in the inhibition of prostate cancer metastasis. Read more: https://goo.gl/COqglT
Views: 193 Roswell Park Comprehensive Cancer Center
Miravirsen, the first microRNA-targeted drug to enter human clinical trials, successfully reduced hepatitis C (HCV) RNA levels in patients with chronic HCV infection in a phase 2a trial, according to results published March 27 in the New England Journal of Medicine. The development opens the door to a potential new treatment for the disease. "This is particularly exciting for patients with chronic hepatitis infection," said Gyongyi Szabo, MD, PhD, professor of medicine and a translational scientist studying chronic hepatitis C infection and liver function, who was not involved in the trial. "This may represent a new type of therapy that has the potential for future treatments in patients with the most difficult hepatitis C type to treat -- genotype 1. Especially when one considers that that current treatments have many side effects and limited efficacy." Globally, as many as 170 million people are estimated to suffer from HCV infection. Chronic HCV is a major cause of liver cirrhosis, liver failure, hepatocellular carcinoma and is the leading cause of liver transplants in the United States. Inside the liver, the hepatitis C virus uses a liver-specific microRNA-122 (miR-122) molecule normally important for cholesterol metabolism to replicate. Miravirsen, developed by Santaris Pharma, works by sequestering and effectively inhibiting miR-122 so the virus can't use it to propagate. In the study, a total of 36 patients with chronic HCV genotype 1 received various doses of miravirsen over a 29-day period. Two weeks after treatment, five patients receiving the two highest doses of the drug showed no observable signs of HCV RNA. Essential for turning genes on and off, microRNA was discovered in 1993 by Victor R. Ambros, PhD, the Silverman Chair in Natural Sciences and professor in the Program in Molecular Medicine at UMass Medical School.
Views: 2077 UMass Medical School
Dr Goel speaks with ecancertv at WIN 2016 about micro RNAs (miRNAs), and their clinical use as prognostic or diagnostic markers for cancer diagnoses. He reports that RNA fragments isolated from a wide array of sample types can, with thorough assaying, lead to early diagnosis in patients and thus to more effective treatment, especially for those with GI malignancies. Dr Goel discusses how tumour heterogeneity can be monitored and treatments adjusted accordingly, based on miRNA sampling.
Views: 26 ecancer
The key to treating Breast Cancer is to catch it early, and and researchers at Arizona State University (ASU) have made a major breakthrough, resulting in a test that could potentially save many lives. FOX 10's John Hook reports.
Views: 1289 FOX 10 Phoenix
KI biologist and cancer research pioneer Robert Weinberg discovered the first human oncogene and literally wrote the (text)book on cancer. His contributions and mentorship in the field have inspired multiple generations of researchers to apply their skills and talents to the ongoing fight against this deadly disease. Following his masterclass presentation about the mechanisms of metastasis, Professor Weinberg sat down with former trainee Tyler Jacks, now the director of the Koch Institute, for an intimate conversation about their shared passion for cancer research and professional journeys at MIT. This program was the second of five special with/in/sight events celebrating our fifth anniversary and highlighting the pillars of progress in MIT's interdisciplinary approach to cancer research
Views: 2638 KochInstituteMIT
Behold The Future...Scientists at the Mayo Clinic in Florida in the Department for Cancer Biology have successfully reprogrammed lung, breast, and bladder cancer cells back into normal, healthy cells by bringing back the function that prevents them from multiplying in excess. While the tests have only been conducted on human cells in the lab (rather than human trial), their work has tremendous implications for the future of cancer treatment. Researchers are hopeful that the technique could one day be used to target tumours, so that the cancer will be “switched off” without the need for chemotherapy, surgery, or other drugs. This important study solves a long-standing biological mystery, but we mustn’t get ahead of ourselves. There’s a long way to go before we know whether these findings, in cells grown in a laboratory, will help treat people with cancer. But it’s a significant step forward in understanding how certain cells in our body know when to grow, and when to stop. Understanding these key concepts is crucial to help continue the encouraging progress against cancer we’ve seen in recent years. – Henry Scowcroft, Cancer Research UK’s senior science information manager When the US researchers added molecules called microRNAs, it stopped the cancer in its tracks. According to Professor Panos Anastasiadis, Chair of the Department for Cancer Biology on Mayo Clinic’s Florida Campus: We can effectively reprogram them (cancer cells) to become and behave as normal. So we can take very aggressive tumour cells that are growing and migrating, replenish them with the microRNAs that are deregulated, and that effectively turn them into normal cells. It’s quite amazing how many discoveries have been made in the last decade alone which show promising results for cancer eradication. Cannabis is a great example. For years, many studies have shown how multiple properties within cannabis completely kill cancerous tumours, yet no clinical trials have been conducted on humans. Despite this fact, a number of people have taken matters into their own hands and have had a tremendous amount of success treating their cancer in this way – Mykayla Comstock is a great example. You can find links to studies that are embedded in various articles that we’ve written on this subject by clicking here. Here is an article we wrote regarding a little known Chinese herb that can kill 12,000 cancer cells for every healthy cell, and a simple Google search would show you just how many vegetables are capable of fighting cancer, broccoli being one great example. The point I am trying to make is that there are a number of ways you can keep healthy. With cancer rates on the rise, at a staggering (approximately) one in two chance of developing the disease in your lifetime, we need to start shifting the conversation and talking about cancer prevention rather than just cancer treatment. And that all starts with looking at our toxic environment. A number of links have been made between cancer and the pesticides that we spray all over our food and the environment. Not to mention the heavy metals in our cosmetics, the Genetically Modified Food, processed food, everyday household products, ingredients within toothpastes and deodorants, and a thousand other consumer goods – we are surrounded by carcinogens on a daily basis. It’s clear that we need to find a better way to do things here. http://www.collective-evolution.com/2015/09/14/big-news-cancer-cells-were-recently-programmed-back-to-normal-healthy-ones/?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+Collective-evolution+%28Collective+Evolution%29 --------------------------------------------------------------------------- Mayo Clinic Researchers Find New Code That Makes Reprogramming of Cancer Cells Possible...Cancer researchers dream of the day they can force tumor cells to morph back to the normal cells they once were. Now, researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy. Panos Anastasiadis, Ph.D., chair of the Department of Cancer Biology on Mayo Clinic’s Florida campus comments on the findings which are published in Nature Cell Biology. https://www.youtube.com/watch?t=10&v=yGYTLOGZ40U
Views: 1144 UPHIGH Productions
MIT 7.013 Introductory Biology, Spring 2011 View the complete course: http://ocw.mit.edu/7-013S11 Instructor: Tyler Jacks In this lecture, Professor Jacks covers the fundamental definitions of different types of cancers, as well as their stages of progression. License: Creative Commons BY-NC-SA More information at http://ocw.mit.edu/terms More courses at http://ocw.mit.edu
Views: 37575 MIT OpenCourseWare
Polly A. Newcomb Fred Hutchinson Cancer Research Center, Seattle New Colorectal Cancer Precursors: From Microscope to MicroRNA Das Netzwerk gegen Darmkrebs veranstaltete gemeinsam mit dem Deutschen Krebsforschungszentrum (DKFZ), dem Nationalen Centrum für Tumorerkrankungen (NCT), dem Universitätsklinikum Heidelberg und der Felix Burda Stiftung am 5.-6.Juni 2014 den internationalen Expertenworkshop „Innovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer". Führende Wissenschaftler aus USA, UK, Israel, Frankreich, Dänemark und Deutschland stellten ihre neuesten Forschungsergebnisse vor und diskutieren, wie zum Wohle der Patienten Erkenntnisse aus der Wissenschaft -- from Bench to bedside - in den klinischen Alltag überführt werden können. Mehr Informationen: https://www.netzwerk-gegen-darmkrebs.de/2014/06/26/neues-zur-fruherkennung-und-pravention-von-darmkrebs/
Views: 174 Netzwerk gegen Darmkrebs
Cancer Research Institute postdoctoral fellows Noah Palm, April Price, and Joshua Ziel discuss their work on the intestinal "microbiome"—our personalized collection of gut microbes—and what it tells us about cancer and cancer treatment. The Cancer Research Institute (CRI), established in 1953, is the world's only nonprofit organization dedicated exclusively to transforming cancer patient care by advancing scientific efforts to develop new and effective immune system-based strategies to prevent, diagnose, treat, and eventually cure all cancers. Guided by a world-renowned Scientific Advisory Council that includes three Nobel laureates and 26 members of the National Academy of Sciences, CRI has invested $263 million in support of research conducted by immunologists and tumor immunologists at the world's leading medical centers and universities, and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. To learn more, go to www.cancerresearch.org.
Views: 1809 Cancer Research Institute
Professor Goldsby has been a professor at Amherst College since 1982. A specialist on the immune system, he is the author of many scientific papers and with Thomas Kindt and Barbara Osborne, the author of the 5th edition of Kuby Immunology (2007), a widely used textbook. Other works include Cells and Energy (1977) and Race and Races (1977), Thinking AIDS, with Mary Catherine Bateson (1989), and many scientific papers. In 1998, with other colleagues, he co-founded Hematech, a pioneer in the development of cloned transgenic cattle for the production of human antibodies for therapeutic uses. He holds a B.A. in chemistry from the University of Kansas and a Ph.D. from the University of California at Berkeley. He currently also directs doctoral students at the University of Massachusetts at Amherst.
Views: 4432 AmherstCollege
Two kinds of blood tests are poised to help predict the development of breast cancer. The first is a common blood test that measures blood platelet counts, which have been found to be connected with the disease. The second is a test that recognizes proteins the body makes when it's fighting breast cancer. Blood tests that measure platelet counts are common. Researchers from the University of Exeter in the United Kingdom believe that high platelet counts could be as accurate a predictor of the development of breast cancer as an actual breast lump. The second test is branded as Videssa Breast and could cut the use of biopsy by 67 percent. http://www.allure.com/story/new-blood-test-can-help-diagnose-breast-cancer http://www.wochit.com This video was produced by YT Wochit News using http://wochit.com
Views: 571 Wochit News
Memorial Sloan-Kettering President and CEO Craig B. Thompson welcomes attendees to the seventh annual Major Trends in Modern Cancer Research lecture for high school students and introduces the speakers.
Views: 1930 Memorial Sloan Kettering
England's publicly funded healthcare system, the National Health Service announced 11 new Genomics Medicine Centres Monday, as part of a new DNA scheme that aims to tackle cancer and rare diseases. The centres are part of their 100,000 Genomes Project , which was launched by Prime Minister David Cameron earlier this year to collect and decode 100,000 genomes, enabling scientists and doctors to understand more about specific conditions. The NHS aims to transform the future of healthcare and hopes the centres will improve the prediction and prevention of disease, enable new and more precise diagnostic tests, and allow personalisation of drugs and other treatments to specific genetic variants. http://feeds.mashable.com/~r/Mashable/~3/omYUTpby_pc/ http://www.wochit.com
Views: 106 Wochit News
This year, swim for doctors like Jedd Wolchok. He explains here how the SAA lab at MSKCC was instrumental in the recent development of a melanoma treatment.
Views: 1534 SwimAcrossAmerica
Arnold Levine: The regulation and activation of P53 functions by wide variety stress signals protects us from cancers. 4th Annual Meeting of the Israeli Society for Cancer Research The Faculty of Life Science The 2012 Cancer Route -- From Bench to Bedside 8 May 2012, Bar-Ilan University
Views: 6324 barilanuniversity
Learn more about Sue’s story: https://www.mskcc.org/sue Like us on Facebook: http://www.facebook.com/sloankettering Follow us on Twitter: http://twitter.com/sloan_kettering Sue Bruno was born with only one healthy kidney. In 2013, Sue was diagnosed with cancer in that kidney. In this short film directed by award-winning filmmaker David Gelb, see how science saved Sue’s kidney and allowed her to enter an immunotherapy clinical trial that ultimately saved her life.
Views: 2058 Memorial Sloan Kettering
Alberto Mantovani - University of Milan - Istituto Clinico Humanitas, Italy Discussing his talk on the mechanisms linking inflammation and cancer, Dr Mantovani highlights the importance of the tumour microenvironment at the IFOM-Kyoto University Joint Symposium in Milan. Dr Mantovani notes that a tumor is not only made up tumor cells, but also normal cells that provide structure, blood vessels and defense cells, such as macrophages. The key to fighting the tumor cells and inflammation is reprogramming the defense cells to recognise the tumor cells as negative. Recorded during the IFOM - Kyoto University Joint Symposium, October 2012. For more info visit ifom.eu
Views: 1606 IFOM
Building on our rich history of innovation, genome scientists, bioinformaticians and molecular pathologists at Memorial Sloan Kettering Cancer Center have developed a targeted tumor sequencing test, MSK-IMPACT™ (Integrated Mutation Profiling of Actionable Cancer Targets), to detect gene mutations and other critical genetic aberrations in both rare and common cancers. The ultimate goal of the MSK-IMPACT™ test is to use clinical molecular laboratory testing to improve oncologists’ ability to treat people with solid cancers by giving them a better understanding of the genetic underpinnings of each patient’s illness.
Views: 3412 Memorial Sloan Kettering
A cardiovascular research team from Beth Israel Deaconess Medical Center (BIDMC) and Brigham and Women's Hospital (BWH), led by BIDMC Principal Investigator Saumya Das, MD, PhD, has been awarded a $4 million Common Fund grant from the National Institutes of Health (NIH) as part of a newly formed program on Extracellular RNA Communication. The five-year grant will focus on identifying microRNA biomarkers in heart disease.
Views: 460 Beth Israel Deaconess
Two Memorial Sloan Kettering researchers, including Sloan Kettering Institute Director Joan Massagué, share their perspective on the next wave of cancer science.
Views: 2221 Memorial Sloan Kettering
Professor Max Wicha, Director, University of Michigan Comprehensive Cancer Center Breast cancer stem cell regulation Understanding breast cancer stem cells, how breast cancer tumours recruit stem cells from the bone, and inhibiting receptor CXCR1 using an anti-inflamatory drug to knock out cancer stem cells- a whole new approach
Views: 3579 ecancer
Last year an international team led by Cancer Research UK scientists at our Cambridge Research Institute unveiled the results of a huge research project called METABRIC. They used advanced gene sequencing techniques to analyse the patterns of gene activity in breast tumours from thousands of women, revealing the molecular 'signature' of each tumour. The results showed that the disease could be divided into ten distinct subtypes, each with its own characteristics and outlook. That work was just the beginning of the story. Since then, the researchers, led by Professor Carlos Caldas, have been delving into these subtypes in ever greater depth, trying to figure out what makes them different and how we can tackle each one more effectively. In a new paper, published in the leading scientific journal Nature, the team took another look at the thousand breast cancer samples from the METABRIC study. But rather than looking at genes that bear the instructions to make proteins in our cells, the researchers focused instead on a set of genes that encode tiny lengths of RNA - a relative of the larger DNA molecules that makes up our genome. In recent years it has become clear that these short pieces of RNA -- known as microRNAs, or miRNAs for short - can help to control when and where protein-making genes are switched on or off, and they're an increasingly hot topic in the world of cancer research. And now it looks like they may be playing a role in controlling how the immune system responds to certain breast cancers. Small but powerful First discovered in the 1990s in tiny worms called nematodes, microRNAs act as molecular 'switches' inside cells, turning genes off when they're not needed as well as fine-tuning gene activity levels. They're made from chopping up much longer strings of RNA -- a type of molecular 'messenger' in cells. This research also helps to reveal more about the underlying biology of breast cancer, enabling researchers to map out the disease in ever-greater detail Many hundreds of different microRNAs have now been identified, and they can recognise and act on individual genes in various ways. And thanks to projects such as ENCODE, we also know there's a lot more in the genome still to be discovered. Researchers already know that cancer cells contain different levels of microRNAs compared to healthy cells - generally, they tend to be lower - and some types of cancer seem to have a characteristic microRNA fingerprint. This suggests that they could be useful for helping to diagnose or potentially even treat the disease. Professor Caldas and his team wanted to find out whether the ten distinct subtypes of breast cancer they'd identified in the METABRIC study also had a telltale microRNA signature, and whether this matched up with the particular characteristics of that type. Mapping microRNAs In the largest study of its kind ever undertaken, the researchers looked at more than 850 different microRNAs in around 1,300 breast tumour samples taken from patients. These cancers had already been analysed as part of the METABRIC project, so plenty was known about them in terms of their genetic makeup, as well as how well they had responded to treatment. The results of METABRIC showed that there are ten distinct subtypes of breast cancer, referred to by the researchers as iClust1 through to iClust10. Many of these subtypes have a lot of changes in their DNA, with pieces copied many times or going missing altogether. Because the instructions that make microRNAs are encoded in our DNA, scattered amongst the 30,000 or so proper genes that make up our genome, the scientists wondered how they might be affected by this genetic chaos. And, in turn, they wanted to see whether any resulting changes in the microRNAs were having a knock-on effect on gene activity. Finding a pattern After scanning through a huge amount of data, looking at the levels of 850 different miRNAs in nearly 2,000 samples, the team found that only one particular subtype of breast cancer - known as 'iClust4' -- had a consistent pattern of characteristic microRNAs. iClust4 is the most common subtype of breast cancer in the METABRIC study, making up about 15 per cent of the patients. It's also a bit unusual as the tumours tend to contain very high numbers of immune cells, and their genes are much less messy than in other subtypes. Intriguingly, many of the microRNAs found in these tumour samples had previously been implicated in controlling immune responses, suggesting that they might be playing a similar role here. But rather than being simple switches, turning key immune system genes on and off, the microRNAs seem to be acting as genetic 'fine-tuners', subtly changing the activity level of important genes to make sure the immune response is just right. This is a vital function, as overzealous or underactive immune responses have big implications for health and disease, including cancer.
Views: 105 ViralMedia24